Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
127 hedge funds and large institutions have $1.19B invested in Alder Biopharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 44 reducing their positions, and 26 closing their positions.
7% more capital invested
Capital invested by funds: $1.11B → $1.19B (+$81.1M)
0% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 44
9% less funds holding
Funds holding: 139 → 127 (-12)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
46% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 26
57% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $4.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$96.9M |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
+$16.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.4M |
| 4 |
Man Group
London,
United Kingdom
|
+$6.5M |
| 5 |
SC
Samlyn Capital
New York
|
+$5.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$21.5M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$18.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.7M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$9.42M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$8.39M |
ALDR Hedge Fund Activity: Q3 2018 in Review
127 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2018, worth a combined $1.19B — up 7.3% from $1.11B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ALDR and 14 opened new positions — a net loss of 12 holders — while 44 trimmed existing stakes and 44 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $96.9M. The largest seller was Emerald Advisers, exiting entirely with an estimated $21.5M sold.
- 127 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2018, down from 139 in Q2 2018.
- Funds reported $1.19B of Alder Biopharmaceuticals stock for Q3 2018, up 7.3% quarter-over-quarter.
- 14 funds opened new Alder Biopharmaceuticals positions in Q3 2018 and 26 closed out, a net change of -12 holders.
- The largest Alder Biopharmaceuticals buyer in Q3 2018 was T. Rowe Price Associates, an estimated $96.9M added.
- The largest Alder Biopharmaceuticals seller in Q3 2018 was Emerald Advisers, an estimated $21.5M sold.
Based on aggregated 13F filings for Q3 2018.